Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

NEXT STORY
Cell Analysis Global Market – Forecast to 2027
PREV STORY
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

NEXT STORY
Cell Analysis Global Market – Forecast to 2027
PREV STORY
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease

author_avatar
NASDAQ Market News

TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018

author_avatar
NASDAQ Market News

Versus Systems Partners With Predictmedix to Develop Products for Healthcare Applications in the Clinical Trial Market

author_avatar
NASDAQ Market News